CME

Host: Sandra E. Kurtin, PhD, ANP-BC, FAPO

Guest: Beth Faiman PhD, MSN, APN-BC,BMTCN, AOCN, FAAN, FAPO

On-demand webcast of expert faculty presentation and case discussion on treating patients with CLL and MCL with non-covalent BTK inhibitors, as presented at CCO and PCE’s APPlexus Hot Topics 2024.

Host: W. Brian Gibler, MD, FACEP, FACC, FAHA

Host: Natalie Kreitzer, MD, MS

Host: Adrian R. Parry-Jones, FRCP, PhD

Host: Hiren C. Patel, PhD, FRCS

Host: David Seiffge, MD

Host: Thorsten Steiner, MD, PhD, MME

Dive deep into the critical care of anticoagulated patients with intracranial hemorrhage (ICH). Our panel of esteemed experts deliver essential insights into the latest treatment approaches, exploring recent data focused on reversing anticoagulation and the neurosurgical management of ICH. This program provides a comprehensive understanding of key strategies proven to be effective in these complex cases, highlighting the most up-to-date guideline-directed, evidence-based practices.

Host: Matthew Lunning, DO, FACP

In the rapidly evolving landscape of treating patients with relapsed or refractory large/diffuse large B-cell lymphoma (R/R LBCL/DLBCL), recent advancements are providing newfound hope. Immunochemotherapy with R-CHOP has long been the standard first-line treatment, but a significant portion of patients experience relapses and refractory disease. Until recently, salvage chemotherapy followed by autologous stem cell transplant (ASCT) was the only curative option. However, the introduction of novel therapies including T-cell engaging therapies has sparked a paradigm shift in R/R LBCL/DLBCL management.

In this transforming landscape, bispecific antibodies (BsAbs) stand out as a remarkable addition. They offer readily available, "off-the-shelf" options that do not require a manufacturing process tailored to each patient, with the advantage of lower rates of severe side effects compared to CAR T-cell therapy, making them a promising choice, particularly for older patients and those with late-stage disease.

This web-based, on-demand activity highlights key clinical trial evidence for bispecific antibodies targeting CD20 and CD3, and how to contextualize the rationale for and clinical utility of integrating CD20 X CD3 bispecific antibodies into community-based clinical practice. Expert faculty offer insights and advice based on their own real-world clinical practice experiences regarding the management and treatment of R/R DLBCL/LBCL and appropriate …

Host: Hiren C. Patel, PhD, FRCS

Host: W. Brian Gibler, MD, FACEP, FACC, FAHA

Host: Adrian R. Parry-Jones, FRCP, PhD

Host: Thorsten Steiner, MD, PhD, MME

Dive deep into the critical care of anticoagulated patients with intracranial hemorrhage (ICH). Our panel of esteemed experts deliver essential insights into the latest treatment approaches, exploring recent data focused on reversing anticoagulation and the neurosurgical management of ICH. This program provides a comprehensive understanding of key strategies proven to be effective in these complex cases, highlighting the most up-to-date guideline-directed, evidence-based practices.

Host: Thorsten Steiner, MD, PhD, MME

Host: W. Brian Gibler, MD, FACEP, FACC, FAHA

Host: David Seiffge, MD

Host: Adrian R. Parry-Jones, FRCP, PhD

Host: Natalie Kreitzer, MD, MS

Dive deep into the critical care of anticoagulated patients with intracranial hemorrhage (ICH). Our panel of esteemed experts deliver essential insights into the latest treatment approaches, exploring recent data focused on reversing anticoagulation and the neurosurgical management of ICH. This program provides a comprehensive understanding of key strategies proven to be effective in these complex cases, highlighting the most up-to-date guideline-directed, evidence-based practices.

Host: David Seiffge, MD

Host: Natalie Kreitzer, MD, MS

Host: W. Brian Gibler, MD, FACEP, FACC, FAHA

Dive deep into the critical care of anticoagulated patients with intracranial hemorrhage (ICH). Our panel of esteemed experts deliver essential insights into the latest treatment approaches, exploring recent data focused on reversing anticoagulation and the neurosurgical management of ICH. This program provides a comprehensive understanding of key strategies proven to be effective in these complex cases, highlighting the most up-to-date guideline-directed, evidence-based practices.

Host: Natalie Kreitzer, MD, MS

Host: W. Brian Gibler, MD, FACEP, FACC, FAHA

Host: Thorsten Steiner, MD, PhD, MME

Host: Adrian R. Parry-Jones, FRCP, PhD

Dive deep into the critical care of anticoagulated patients with intracranial hemorrhage (ICH). Our panel of esteemed experts deliver essential insights into the latest treatment approaches, exploring recent data focused on reversing anticoagulation and the neurosurgical management of ICH. This program provides a comprehensive understanding of key strategies proven to be effective in these complex cases, highlighting the most up-to-date guideline-directed, evidence-based practices.

Host: Adrian R. Parry-Jones, FRCP, PhD

Host: W. Brian Gibler, MD, FACEP, FACC, FAHA

Host: Hiren C. Patel, PhD, FRCS

Host: David Seiffge, MD

Dive deep into the critical care of anticoagulated patients with intracranial hemorrhage (ICH). Our panel of esteemed experts deliver essential insights into the latest treatment approaches, exploring recent data focused on reversing anticoagulation and the neurosurgical management of ICH. This program provides a comprehensive understanding of key strategies proven to be effective in these complex cases, highlighting the most up-to-date guideline-directed, evidence-based practices.

Host: Valeria Caso, MD, PhD

Guest: Ashkan Shoamanesh, MD

How can you improve long-term secondary stroke prevention in patients with a history of noncardioembolic ischemic stroke or transient ischemic attack (TIA)? An understanding of how to apply emerging clinical trial data is critical, as is the evaluation of potential alternative agents that could expand the therapeutic options for these patients. In this activity, our expert faculty will add to your knowledge by reviewing the coagulation cascade and the relevance of inhibiting factors XI and XIa in stroke management.

Host: Warner K. Huh, MD

Guest: Kimberly Levinson, MD, MPH

More effective triage tests are essential to improving cervical cancer risk-stratification and thus reducing the potential for unnecessary colposcopies. Enduring consensus cervical cancer screening recommendations, published in 2024, describe specific-use algorithms for p16/Ki-67 dual-staining cytology as an effective triage test, and also offer insight on how this test can best fit into clinical practice. Join Drs. Warner Huh and Kimberly Levinson as they first establish the rationale for using p16/Ki-67 dual-staining cytology and then break down the most salient algorithms for its use as offered in the recent recommendations.